Canaccord Genuity analyst Arlinda Lee maintained a Buy rating on BioNTech SE (NASDAQ:BNTX) on Wednesday, setting a price target of $240, which is approximately 28.94% above the present share price of $186.13.
Lee expects BioNTech SE to post earnings per share (EPS) of $0.00 for the second quarter of 2021.
The current consensus among 7 TipRanks analysts is for a Moderate Buy rating of shares in BioNTech SE, with an average price target of $188.43.
The analysts price targets range from a high of $240 to a low of $133.
In its latest earnings report, released on 03/31/2021, the company reported a quarterly revenue of $2.05 billion and a net profit of $1.62 billion. The company's market cap is $44.95 billion.
According to TipRanks.com, Canaccord Genuity analyst Arlinda Lee is currently ranked with 4 stars on a 0-5 stars ranking scale, with an average return of 9.1% and a 47.20% success rate.
BioNTech SE is a Germany-based biotechnology company that develops and manufactures immunotherapies for cancer, infectious diseases, allergies and autoimmune disorders.